Evaluation of the BioPlex 2200 ANA Screen for the Detection of Antinuclear Antibodies and Comparison with Conventional Methods

Abstract:  BioPlex 2200 multiplexed assays system is an automatic method allowing detection of antinuclear antibodies (ANA). The aim of our study was to evaluate the determination of 13 autoantibodies against chromatinic and nonchromatinic nuclear antigens by the BioPlex 2200 system and to compare the results achieved by this method to those obtained with our routinely used immunoassays. One thousand and four serum samples consecutively sent for ANA detection were routinely tested by indirect immunofluorescence (IIF) on HEp2 cells. Among them, 321 were also analyzed by dsDNA enzyme immunoassay (EliA) test and 657 by double immunodiffusion (DID) for extractable nuclear antigen (ENA) antibodies. All the sera were evaluated by the BioPlex 2200 ANA screen kit allowing simultaneous detection of antibodies against the following antigens: dsDNA, chromatin, SSA‐52 kDa, SSA‐60 kDa, SSB, Sm, Sm/RNP, RNP‐A, RNP‐68 kDa, Scl70, centromere B, Jo‐1, and P ribosomal proteins. The kappa coefficient between BioPlex 2200 and routine tests for detection of ANA on HEp2 cells, anti‐dsDNA, and anti‐ENA antibodies was, respectively, 0.31, 0.66, and 0.61. The comparison with our routine tests showed numerous discrepancies between IIF ANA screening and BioPlex but a good concordance for detection of anti‐dsDNA and anti‐ENA specificities. BioPlex 2200 system is a rapid and sensitive method for simultaneous quantitative detection of several autoantibodies. It is perfectly well adapted to determine ANA antigenic specificities of samples found positive using initial IIF screening. The capability of this multiplexed technology to analyze simultaneously 13 ANA autoantibodies leads to the rapid availability of an “autoimmune connective tissue disease serologic profile.”

[1]  Y. Shoenfeld,et al.  Evaluation of the BioPlex™ 2200 ANA Screen: Analysis of 510 Healthy Subjects: Incidence of Natural/Predictive Autoantibodies , 2005, Annals of the New York Academy of Sciences.

[2]  Concepción González,et al.  Clinical evaluation of a microsphere bead-based flow cytometry assay for the simultaneous determination of anti-thyroid peroxidase and anti-thyroglobulin antibodies. , 2005, Clinical biochemistry.

[3]  E. Rivitti,et al.  Prevalence of antinuclear autoantibodies in the serum of normal blood dornors. , 2003, Revista do Hospital das Clinicas.

[4]  P. Lipsky,et al.  Autoantibodies as predictors of disease. , 2001, The Journal of clinical investigation.

[5]  Y. Shoenfeld,et al.  Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases , 2005, Autoimmunity.

[6]  Anne-Marie Rouquette,et al.  Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. , 2003, American journal of clinical pathology.

[7]  E. Ben-Chetrit,et al.  Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. , 1990, Arthritis and rheumatism.

[8]  J. Buyon,et al.  Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. , 1991, The Journal of clinical investigation.

[9]  G. Hughes,et al.  Serological markers in progressive systemic sclerosis: clinical correlations. , 1983, Annals of the rheumatic diseases.

[10]  M. Mattioli,et al.  Antinuclear antibodies (ANA): immunologic and clinical significance. , 1976, Seminars in arthritis and rheumatism.

[11]  Andrea Giordano,et al.  Autoantibodies Profile in the Sera of Patients with Sjogren]s Syndrome: The ANA Evaluation—A Homogeneous, Multiplexed System , 2004, Clinical & developmental immunology.

[12]  Harry R. Hill,et al.  Evaluation of Multiplexed Fluorescent Microsphere Immunoassay for Detection of Autoantibodies to Nuclear Antigens , 2004, Clinical Diagnostic Laboratory Immunology.

[13]  A. Todd-Pokropek,et al.  Measurement of anti-DNA antibodies: a reappraisal using five different methods. , 1987, Annals of the rheumatic diseases.

[14]  E. Tan,et al.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. , 1982, Advances in immunology.

[15]  R. Zahn,et al.  Influence of molecular weight of DNA on the determination of anti-DNA antibodies in systemic lupus erythematosus (SLE) sera by radioimmunoassay. , 1975, Nucleic acids research.

[16]  D. Isenberg,et al.  52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block , 2005, Arthritis research & therapy.

[17]  R J Fulton,et al.  Advanced multiplexed analysis with the FlowMetrix system. , 1997, Clinical chemistry.

[18]  Elias Zintzaras,et al.  Evaluation of a Microsphere‐Based Flow Cytometric Assay for Diagnosis of Celiac Disease , 2004, Journal of immunoassay & immunochemistry.

[19]  A. Wiik,et al.  Anti‐nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases , 2005, Scandinavian journal of rheumatology.

[20]  E. Tan,et al.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. , 1989, Advances in immunology.

[21]  R. Derksen,et al.  A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum , 2002, Annals of the rheumatic diseases.

[22]  George Notas,et al.  Comparison of a multiplex, bead-based fluorescent assay and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum. , 2006, Journal of immunological methods.

[23]  Y. Shoenfeld,et al.  The Homogeneous Multiplexed System-a New Method for Autoantibody Profile in Systemic Lupus Erythematosus , 2005, Clinical & developmental immunology.

[24]  O. Rekvig,et al.  Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity , 2004, Annals of the rheumatic diseases.